Clinical trials

Completed

Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC)

REP0111

What is the purpose of this study?

The study is being conducted to evaluate the safety and define the pharmacokinetic (PK) profile of orally administered reparixin in combination with paclitaxel in HER 2 (Human epidermal growth factor receptor-2) negative metastatic breast cancer patients.

Trial overview

Condition

Metastatic Breast Cancer

Study Identifiers

NCT02001974

Study type

Interventional

Intervention

Drug: Paclitaxel+Reparixin

Phase

Ib

Start date

Jan 2012

End Date

Jan2015

Enrollment Goal

24

Going deep into the trial

Eligibility/Recruitment

Age

≥18 years old

Gender

Accepts healthy volunteers

Key Criteria

close

Inclusion

close

Exclusion

Some information about patients involvement

Study participation will last approximately 6-8 months. There will be weekly visits to the doctor during the treatment period.

Desired Outcomes

close

Primary Outcomes

close

Secondary Outcomes

Find your nearest centre:

Loading...

loading...